SCHEMBL3759089

SCHEMBL3759089

Cc1c(-c2ccccc2)[c]nc(N)c1N1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
ADRA2A P08913 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
KMT2A Q03164 2/20 0.38
DHFR P00374 2/20 0.37
HSD17B10 Q99714 4/20 0.37
HTT P42858 3/20 0.37
TSHR P16473 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NUDT1 P36639 1/20 0.36
MAT2A P31153 4/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3756111 0.99 ADORA2A (0.40) ADORA2AKDM4EALDH1A1HPGDADRA2A
SCHEMBL3762351 0.83 KMT2A (0.38) KDM4EALDH1A1HPGDRXFP1KMT2A
SCHEMBL3754966 0.80 CNR1 (0.38) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3760546 0.80 LRRK2 (0.37) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3761663 0.75 KMT2A (0.49) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3752036 0.73 HTR1A (0.41) ALDH1A1HPGDKMT2ATSHRCYP1A2
SCHEMBL3760334 0.73 CKS1B (0.39) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3759007 0.72 HTT (0.48) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3751377 0.71 NPY5R (0.41) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL3760258 0.71 HTT (0.38) ADORA2AKDM4EALDH1A1HPGDADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ADORA2A 3962/4885KDM4E 1014/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.